Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00065182 · ClinicalTrials.gov registry record · Phase 2
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 399
- Enrollment target
NCT00065182: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00065182 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 399 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00065182, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 399 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.
Primary Outcome
Overall survival was defined as the time from randomization to death and it occurs when all randomized participants had at least one year of follow-up past their date of randomization to treatment.
Interventions
- DRUG Docetaxel
- DRUG Topotecan/Docetaxel combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2003-08-14 |
| Est. Completion | 2007-08-30 |
| Phase | Phase 2 |
What the finished NCT00065182 record still lists
NCT00065182 is an interventional study that assigns participants to a tested intervention. The registered 399 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT00065182 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00065182 about?
NCT00065182 is a clinical study titled "Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer". The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.
What is the current status of trial NCT00065182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 399 participants. The study started on 2003-08-14. Estimated completion is 2007-08-30.
What interventions are being tested in trial NCT00065182?
The interventions under investigation include: Docetaxel (DRUG), Topotecan/Docetaxel combination (DRUG).
Who is sponsoring clinical trial NCT00065182?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00065182's enrollment target sits among peer trials
399 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI